These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2362630)

  • 1. Effect of hypercalcemia on the anion gap.
    Oster JR; Gutierrez R; Schlessinger FB; Taylor A; Federman DG; Vaamonde CA
    Nephron; 1990; 55(2):164-9. PubMed ID: 2362630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parathyroid hormone and parathyroid hormone related protein assays in the investigation of hypercalcemic patients in hospital in a Chinese population.
    Lee JK; Chuang MJ; Lu CC; Hao LJ; Yang CY; Han TM; Lam HC
    J Endocrinol Invest; 1997; 20(7):404-9. PubMed ID: 9309539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential diagnosis of hypercalcemia.
    Lafferty FW
    J Bone Miner Res; 1991 Oct; 6 Suppl 2():S51-9; discussion S61. PubMed ID: 1763670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum chloride in the differential diagnosis of hypercalcemia.
    Lind L; Ljunghall S
    Exp Clin Endocrinol; 1991; 98(3):179-84. PubMed ID: 1778237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential diagnosis of hypercalcemia by the chloride/phosphate ratio.
    Reeves CD; Palmer F; Bacchus H; Longerbeam JK
    Am J Surg; 1975 Aug; 130(2):166-71. PubMed ID: 1155729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of parathyroid hormone-related peptide to the evaluation of hypercalcemia.
    Audran M; Minebois-Villégas A; Lortholary A; Legrand E; Pascaretti C; Giraud P; Subra JF; Boasson M; Jallet P
    Rev Rhum Engl Ed; 1995 Mar; 62(3):189-96. PubMed ID: 7788336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypercalcemia due to primary hyperparathyroidism or malignant disease. Evaluated by means of biochemical tests and the steroid suppression test.
    Kvetny J; Orthman-Brask H; Frederiksen PK; Jest P; Jensen E; Jacobsen JG
    Acta Med Scand; 1982; 212(3):163-6. PubMed ID: 7148507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raised plasma concentrations of parathyroid hormone related peptide in hypercalcemic multiple myeloma.
    Horiuchi T; Miyachi T; Arai T; Nakamura T; Mori M; Ito H
    Horm Metab Res; 1997 Sep; 29(9):469-71. PubMed ID: 9370119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma intact parathyroid hormone (PTH) and PTH-related peptide in familial benign hypercalcemia: greater responsiveness to endogenous PTH than in primary hyperparathyroidism.
    Firek AF; Kao PC; Heath H
    J Clin Endocrinol Metab; 1991 Mar; 72(3):541-6. PubMed ID: 1997510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypercalcaemia in hospital patients. Clinical and diagnostic aspects.
    Fisken RA; Heath DA; Somers S; Bold AM
    Lancet; 1981 Jan; 1(8213):202-7. PubMed ID: 6109866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of administration of lithium salts and magnesium sulfate on the serum anion gap.
    Silverstein FJ; Oster JR; Materson BJ; Lopez RA; Gutierrez R; Ortiz-Interian CJ; Cason LS; Perez GO; Vaamonde CA
    Am J Kidney Dis; 1989 May; 13(5):377-81. PubMed ID: 2497643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acid-base and electrolyte disturbances in patients with hypercalcemia.
    Milionis HJ; Rizos E; Liamis G; Nikas S; Siamopoulos KC; Elisaf MS
    South Med J; 2002 Nov; 95(11):1280-7. PubMed ID: 12539994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of malignancy-associated hypercalcemia with YM175, a new bisphosphonate: elevated threshold for parathyroid hormone secretion in hypercalcemic patients.
    Fukumoto S; Matsumoto T; Takebe K; Onaya T; Eto S; Nawata H; Ogata E
    J Clin Endocrinol Metab; 1994 Jul; 79(1):165-70. PubMed ID: 8027221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein.
    Budayr AA; Zysset E; Jenzer A; Thiébaud D; Ammann P; Rizzoli R; Jaquet-Müller F; Bonjour JP; Gertz B; Burckhardt P
    J Bone Miner Res; 1994 Apr; 9(4):521-6. PubMed ID: 8030440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of laboratory tests in the differential diagnosis of hypercalcemia.
    Boyd JC; Ladenson JH
    Am J Med; 1984 Nov; 77(5):863-72. PubMed ID: 6496541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anion gap and immunoglobulin concentration.
    Keshgegian AA
    Am J Clin Pathol; 1980 Sep; 74(3):282-4. PubMed ID: 7416079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in blood pressure and renal function following subtotal parathyroidectomy in renal transplant patients presenting with persistent hypercalcemic hyperparathyroidism.
    Rostaing L; Moreau-Gaudry X; Baron E; Cisterne JM; Monroziès-Bernadet P; Durand D
    Clin Nephrol; 1997 Apr; 47(4):248-55. PubMed ID: 9128792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The chloride phosphate ratio as the screening test for primary hyperparathyroidism.
    Broulík PD; Pacovský V
    Horm Metab Res; 1979 Oct; 11(10):577-9. PubMed ID: 521012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypercalcemia: an evidence-based approach to clinical cases.
    Assadi F
    Iran J Kidney Dis; 2009 Apr; 3(2):71-9. PubMed ID: 19395781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.